Time to stop giving toxic drugs to kidney transplant patients?

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted organs from being rejected, but they can be toxic to the kidneys over the long term and can make patients susceptible to infection, cancer, and other threats.

A new analysis has found that transplant patients can safely minimize or avoid using calcineurin inhibitors. The study, conducted by Richard Borrows, MD and his colleagues at the Renal Institute of Birmingham, in England, appears in an upcoming issue of the Journal of the (JASN), a publication of the American Society of Nephrology.

The investigators examined dozens of studies conducted between1966 and 2010 that compared different treatments following . When they weighed the risks and benefits of avoiding or reducing calcineurin inhibitors immediately after kidney transplantation, the researchers found that the strategy improves kidney function without causing rejection in the short-to-medium period after transplantation. In many cases, patients took newer that are less toxic to the kidneys.

Approximately 94% of take calcineurin inhibitors after being discharged from the hospital. "This study suggests that after 30 years of using calcineurin inhibitors, it may now be possible to undertake safe and effective transplantation without these drugs, at least in some groups of patients," said Dr. Borrows.

More information: The article, entitled "Meta-analysis of Calcineurin Inhibitors in Kidney Transplantation," will appear online at doi:10.1681/ASN.2010111160

Related Stories

Switching immunosuppressants reduces cancer risk in kidney

date Nov 02, 2009

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and ...

Recommended for you

Drug and device firms paid $6.5B to care providers

date Jun 30, 2015

From research dollars to free lunches and junkets, drug and medical device companies paid doctors and leading hospitals nearly $6.5 billion last year, according to government data posted Tuesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.